These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7026334)

  • 1. Comparison of two twice-daily insulin regimens: ultralente/soluble and soluble/isophane.
    Ward GM; Simpson RW; Ward EA; Turner RC
    Diabetologia; 1981 Oct; 21(4):383-6. PubMed ID: 7026334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in morning hyperglycaemia with basal human ultratard and prandial human actrapid insulin--a comparison of multiple injection regimens.
    Davies RR; McEwen J; Moreland TA; Durnin C; Newton RW
    Diabet Med; 1988 Oct; 5(7):671-5. PubMed ID: 2975553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
    Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
    Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultralente based insulin regimens--clinical applications, advantages and disadvantages.
    Turner RC; Phillips MA; Ward EA
    Acta Med Scand Suppl; 1983; 671():75-86. PubMed ID: 6349269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
    Francis AJ; Hanning I; Alberti KG
    Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A within patient cross over trial of 4 insulin regimens in antibody-negative, C-peptide negative patients.
    Oswald GA; Yudkin JS
    Diabetes Res; 1987 Feb; 4(2):85-9. PubMed ID: 3555956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence.
    Smith CP; Dunger DB; Mitten S; Hewitt J; Spowart K; Grant DB; Savage MO
    Diabet Med; 1988; 5(4):352-5. PubMed ID: 2968885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice-daily insulin regimens in management of severe diabetes.
    Oakley N; Mather H; Hadley L; Lynch J; Pilkington T
    J R Soc Med; 1981 May; 74(5):363-7. PubMed ID: 7017138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of premixed with patient-mixed insulins.
    Corcoran JS; Yudkin JS
    Diabet Med; 1986 May; 3(3):246-9. PubMed ID: 2951178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG; Gebbie J; Home PD
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast.
    Francis AJ; Home PD; Hanning I; Alberti KG; Tunbridge WM
    Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1173-6. PubMed ID: 6404377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-four-hour metabolic profiles in diabetic children receiving insulin injections once or twice daily.
    Werther GA; Jenkins PA; Turner RC; Baum JD
    Br Med J; 1980 Aug; 281(6237):414-8. PubMed ID: 7000260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
    Lindström T; Olsson PO; Arnqvist HJ
    Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin.
    Parillo M; Mura A; Iovine C; Rivellese AA; Lavicoli M; Riccardi G
    Diabetes Care; 1992 Feb; 15(2):173-7. PubMed ID: 1547673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of prednisolone-induced hyperglycaemia in hospitalized patients: Insights from a randomized, controlled study.
    Radhakutty A; Stranks JL; Mangelsdorf BL; Drake SM; Roberts GW; Zimmermann AT; Stranks SN; Thompson CH; Burt MG
    Diabetes Obes Metab; 2017 Apr; 19(4):571-578. PubMed ID: 27995731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.